Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting 1 Aug Written by Carla Aguilera Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. PMID: 28471719; PMCID: PMC5676955. 2017 Carla Aguilera Previous Previous Accelerating drug development for neuroblastoma - New Drug Development Strategy: an ITCC, ENCCA and Adolescents and SIOPEN project Next Next Busulfan and melphalan versus carboplatin, etoposide, and melphalan as HD chemotherapy for HR neuroblastoma (HR-NBL1 ph3 trial /SIOPEN)
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting 1 Aug Written by Carla Aguilera Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. J Clin Oncol. 2017 Aug 1;35(22):2580-2587. doi: 10.1200/JCO.2016.72.0177. Epub 2017 May 4. PMID: 28471719; PMCID: PMC5676955. 2017 Carla Aguilera
